Pharmaceuticals News and Research

RSS

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, the Wall Street Journal reports. "Many diseases, such as AIDS, tuberculosis and cancer, require multidrug combinations. Such drug cocktails can prevent the development of drug resistance, because the microbe or cancer cell needs to undergo more mutations to escape several drugs than to escape just one. By attacking the disease in different ways, drug combinations also improve the chances of therapeutic benefit," the newspaper reports (Schoofs, 3/18).

19 Mar 2010

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

Three scientists who led the 11-year quest to develop a groundbreaking HIV drug today received the 2010 Discoverers Award -- the highest honor given to scientists by the Pharmaceutical Research and Manufacturers of America. The honorees are Tony Wood, Ph.D., Elna van der Ryst, M.D., Ph.D. and Manos Perros, Ph.D.

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Somaxon Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia characterized by difficulty with sleep maintenance.

19 Mar 2010

Health care fraud, prescription theft lead to significant losses

ABC News: "A four month 'Nightline' investigation into Medicare fraud makes one thing perfectly clear: this is a crime that pays and pays and pays. The federal government admits that a staggering $60 billion is stolen from tax payers through Medicare scams every year. Some experts believe the number is more than twice that.

18 Mar 2010

U.S.-based CRO licenses NewCardio's QTinno software solution for automating cardiac safety analysis

NewCardio, Inc., a cardiac diagnostic technology provider, announced today that a U.S.-based CRO that provides early phase and specialty clinical drug development services to the pharmaceutical industry, has signed an MSA, licensing NewCardio's QTinno™ software solution in order to deliver fully automated cardiac safety analysis in early phase QT studies.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

SciQuest introduces PBA methodology for Life Sciences to improve procurement operations

SciQuest, Inc., the global software leader empowering enterprises to realize the potential of strategic procurement, today unveiled a comprehensive methodology that provides leaders with a framework to build and execute a sound business plan to improve existing procurement processes, systems and protocol. This new service, the Procurement Business Assessment (PBA), enables life sciences companies to quickly uncover cost-saving opportunities in their procurement operations.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

Teva Pharmaceutical Industries Ltd. announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany’s second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of €3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. On a pro forma basis, the combined company would have had 2009 revenues of $16.2 billion. Teva expects to complete the transaction by year-end 2010.

18 Mar 2010

First Edition: March 18, 2010

Today's headlines indicate that Democrats are inching closer to securing the votes necessary to pass their health bill while the GOP is planning steps to bottle neck the measure's progress.

18 Mar 2010

APCER Pharma to manage pharmacovigilance strategies for six global pharmaceutical companies

APCER Pharma announced that in the past three months it has further expanded its customer base and operations. APCER is a leading global provider of comprehensive drug safety, regulatory services and risk management programs for pharmaceutical, biotechnology, medical device and consumer products companies.

18 Mar 2010

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

BeaconEquity.com announces an investment report featuring biotech company AVI BioPharma Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has received a Phase 1 Small Business Innovation Research Grant (SBIR) from the National Institute of Allergy and Infectious Disease (NIAID) branch of the National Institutes of Health (NIH) for the further study and characterization of a back-up series of compounds related to its novel antibacterial, ACH-702.

18 Mar 2010

ISR Reports launches new and substantial research report: Late Phase Market Dynamics

Industry Standard Research today announced the launch of a new and substantial research report titled Late Phase Market Dynamics. This report presents data and analysis from 149 interviews with decision makers from 95 unique pharmaceutical and biotechnology companies around the world.

18 Mar 2010

AVEO Pharmaceuticals completes initial public offering of 9M common stock shares at $9.00 per share

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per share, resulting in aggregate net proceeds to AVEO of approximately $72,580,000 after deducting underwriting discounts and commissions and estimated offering expenses.

18 Mar 2010

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

InvestorSoup.com announces an investment report featuring Cyclacel Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

18 Mar 2010

Pharmaceuticals News and Research

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

Three scientists receive 2010 Discoverers Award for developing new class of HIV drug

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

FDA approves Somaxon Pharmaceuticals' Silenor for treatment of insomnia

Health care fraud, prescription theft lead to significant losses

U.S.-based CRO licenses NewCardio's QTinno software solution for automating cardiac safety analysis

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

SciQuest introduces PBA methodology for Life Sciences to improve procurement operations

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Teva Pharmaceutical Industries to acquire ratiopharm for €3.625 billion

First Edition: March 18, 2010

APCER Pharma to manage pharmacovigilance strategies for six global pharmaceutical companies

BeaconEquity.com: AVI BioPharma's revenues for fourth-quarter of 2009 are $5.1M

Achillion Pharmaceuticals receives NIH SBIR grant for study of novel antibacterial compound series

ISR Reports launches new and substantial research report: Late Phase Market Dynamics

AVEO Pharmaceuticals completes initial public offering of 9M common stock shares at $9.00 per share

InvestorSoup.com: CYCC's total revenues for third-quarter of 2009 decrease by 14%

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence